PMID- 27994943
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2155-6660 (Print)
IS  - 2155-6660 (Electronic)
IS  - 2155-6660 (Linking)
VI  - 5
IP  - 1
DP  - 2016
TI  - Vildagliptin efficacy in combination with metformin among Jordanian patients with 
      type 2 diabetes mellitus inadequately controlled with metformin.
PG  - 29-33
AB  - Objective: To assess the efficacy and safety of vildagliptin added to metformin 
      in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with 
      metformin monotherapy. Methods: This was a 12-week prospective observational 
      study where vildagliptin 50 mg twice daily was added to patients with T2DM 
      inadequately controlled (glycosylated hemoglobin type A1c (Hba1c) 7-10%) by a 
      daily dose of metformin >/=1700 mg between June 2012 and May 2013. Efficacy was 
      assessed by change in Hba1c and fasting plasma glucose (FPG) levels, and safety 
      was assessed by reported adverse events (AEs). Results: A total of 58 patients 
      were enrolled in this study. Their age ranged between 39.0 and 71.0 years, with a 
      mean of 52.6 years, and a standard deviation (SD) of 7.8. The average duration of 
      diabetes mellitus (DM) was 4.0 years (SD 3.0) and half of the patients have had 
      DM for more than three years. The mean baseline levels of Hba1c and FPG were 8% 
      and 10.8 mmol/L, respectively. Patients treated with vildagliptin achieved 
      clinically significant reductions in Hba1c of 1.1% (p value <.005) and reduction 
      in FPG of 1.8 mmol/L (p value <.005) from baseline. Overall, 62.1% had achieved 
      the target of Hba1c of <7% after vildagliptin use. Greater reductions in Hba1c 
      were linked to higher baseline levels as well as to the daily frequency of 
      metformin use. Mild AEs were reported by 16 patients. There was no incidence of 
      hypoglycemia and there were no significant changes in body weight after 
      treatment. Conclusions: Vildagliptin as add-on therapy to metformin improved 
      glycemic control and was highly tolerable in T2DM patients who were inadequately 
      controlled by metformin monotherapy.
FAU - Al Omari, Mousa
AU  - Al Omari M
AD  - Department of Community Medicine, Public Health and Family Medicine, Faculty of 
      Medicine, Jordan University of Science & Technology Irbid , Jordan.
FAU - Khader, Yousef
AU  - Khader Y
AD  - Department of Community Medicine, Public Health and Family Medicine, Faculty of 
      Medicine, Jordan University of Science & Technology Irbid , Jordan.
FAU - Dauod, Ali Shakir
AU  - Dauod AS
AD  - Department of Community Medicine, Public Health and Family Medicine, Faculty of 
      Medicine, Jordan University of Science & Technology Irbid , Jordan.
FAU - Beni Yonis, Othman Ahmed
AU  - Beni Yonis OA
AD  - Department of Community Medicine, Public Health and Family Medicine, Faculty of 
      Medicine, Jordan University of Science & Technology Irbid , Jordan.
FAU - Khassawneh, Adi Harbi Mohammad
AU  - Khassawneh AH
AD  - Department of Community Medicine, Public Health and Family Medicine, Faculty of 
      Medicine, Jordan University of Science & Technology Irbid , Jordan.
LA  - eng
PT  - Journal Article
DEP - 20161104
PL  - England
TA  - J Drug Assess
JT  - Journal of drug assessment
JID - 101672979
PMC - PMC5136976
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Hba1c
OT  - add-on therapy
OT  - adverse events
OT  - dipeptidyl peptidase-4(DPP-4) inhibiters
OT  - hypoglycemia
OT  - metformin
OT  - vildagliptin
EDAT- 2016/12/21 06:00
MHDA- 2016/12/21 06:01
PMCR- 2016/01/01
CRDT- 2016/12/21 06:00
PHST- 2016/07/18 00:00 [received]
PHST- 2016/09/23 00:00 [revised]
PHST- 2016/10/19 00:00 [accepted]
PHST- 2016/12/21 06:00 [entrez]
PHST- 2016/12/21 06:00 [pubmed]
PHST- 2016/12/21 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 1252379 [pii]
AID - 10.1080/21556660.2016.1252379 [doi]
PST - epublish
SO  - J Drug Assess. 2016 Nov 4;5(1):29-33. doi: 10.1080/21556660.2016.1252379. 
      eCollection 2016.